Valuation: Liquidia Corporation

Market Cap 4.09B 3.67B 3.39B 3.07B 5.74B 390B 5.81B 40.59B 16.17B 204B 15.36B 15.03B 647B P/E 2026 *
22.5x
P/E 2027 * 21.7x
Enterprise Value 4.09B 3.67B 3.39B 3.07B 5.74B 390B 5.81B 40.59B 16.17B 204B 15.36B 15.03B 647B EV / Sales 2026 *
5.71x
EV / Sales 2027 * 5.37x
Free-Float
90.79%
Yield 2026 *
-
Yield 2027 * -
1 day+0.62%
1 week+17.65%
Current month+51.09%
1 month-37.94%
3 months-47.34%
6 months+21.43%
Current year+32.56%
1 week 38.69
Extreme 38.69
47.18
1 month 22.31
Extreme 22.31
71.93
Current year 22.31
Extreme 22.31
93.61
1 year 22.21
Extreme 22.2052
93.61
3 years 6.06
Extreme 6.06
93.61
5 years 3.26
Extreme 3.26
93.61
10 years 2.25
Extreme 2.25
93.61
Manager TitleAgeSince
Chief Executive Officer 64 2022-01-02
Director of Finance/CFO 50 2020-11-29
Compliance Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 70 2020-11-17
Director/Board Member 64 2020-11-17
Director/Board Member 74 2020-06-27
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Sell

Controller/Auditor

-5,892 0.0066%
10/12/26 Sell

General Counsel

-13,692 0.0153%
10/12/26 Sell

Executive/Senior Manager

-8,863 0.0099%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%+17.65%+97.49%+637.42% 4.07B
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+1.84%+30.70%+54.27% 293B
-0.45%+1.19%+2.89%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.20%+3.11%+46.33%+132.51% 403.16B
Weighted average by Cap. +0.25%+1.59%+44.55%+89.57%

Financials

2026 *2027 *
Net sales 717M 643M 595M 539M 1.01B 68.29B 1.02B 7.11B 2.83B 35.74B 2.69B 2.63B 113B 762M 684M 632M 573M 1.07B 72.58B 1.08B 7.56B 3.01B 37.98B 2.86B 2.8B 121B
Net income 199M 179M 165M 150M 279M 18.96B 283M 1.97B 786M 9.92B 747M 731M 31.49B 217M 195M 180M 163M 305M 20.69B 309M 2.15B 858M 10.82B 815M 798M 34.37B
Net Debt - -
Projected Income Statement - Annual - Liquidia Corporation
Logo Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler.
Employees
216
Date Price Change Volume
26-10-28 US$45.72 +0.62% 2,262,852
26-10-27 US$45.44 +3.89% 3,184,494
26-10-26 US$43.74 +2.56% 4,116,397
26-10-23 US$42.65 +7.46% 3,805,641
26-10-22 US$39.69 +2.14% 3,534,228
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Liquidia Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
45.72USD
Average target price
54.38USD
Spread / Average Target
+18.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Liquidia Corporation
  1. Stock Market
  2. Stocks
  3. LQDA Stock